These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1198 related items for PubMed ID: 15087031

  • 1. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL, Zhou SY, Du QF, Zheng WY, Zhang S, Song LL, Xu B, Liu QF, Meng FY.
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [Abstract] [Full Text] [Related]

  • 2. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M.
    N Engl J Med; 2001 Apr 05; 344(14):1038-42. PubMed ID: 11287973
    [Abstract] [Full Text] [Related]

  • 3. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R.
    Clin Cancer Res; 2002 May 05; 8(5):935-42. PubMed ID: 12006504
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J.
    Haematologica; 2003 Nov 05; 88(11):1213-20. PubMed ID: 14607749
    [Abstract] [Full Text] [Related]

  • 5. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S, Korean Society of Hematology CML working party.
    Ann Hematol; 2010 Jul 05; 89(7):725-31. PubMed ID: 20179930
    [Abstract] [Full Text] [Related]

  • 6. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Jan 01; 11(1):12-9. PubMed ID: 15671523
    [Abstract] [Full Text] [Related]

  • 7. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.
    Ai Zheng; 2004 Dec 15; 23(12):1696-9. PubMed ID: 15601563
    [Abstract] [Full Text] [Related]

  • 9. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
    Turkina AG, Kruglov SS, Druzhkova GA, Domracheva EV, Zakharova AV, Vinogradova OIu, Sysoeva EP, Diachenko LV, Chelysheva EIu, Zakharova ES, Abakumov EM, Kolosheĭnova TI, Kolosova LIu, Ivanova TV, Zhuravlev VS, Nemchenko IS, Zingerman BV, Kurova ES, Triputen' NZ, Loriia SS, Kovaleva LG, Khoroshko ND.
    Ter Arkh; 2005 Dec 15; 77(7):42-7. PubMed ID: 16116908
    [Abstract] [Full Text] [Related]

  • 10. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH, Tang JL, Chen RL, Li CC, Lee CP.
    Leuk Res; 2008 Nov 15; 32(11):1724-34. PubMed ID: 18603297
    [Abstract] [Full Text] [Related]

  • 11. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A.
    Semin Hematol; 2003 Apr 15; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [Abstract] [Full Text] [Related]

  • 12. [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
    Meng FY, Zheng WY, Liu XL, Xu B, Song LL, Zhang Y, Huang F.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov 15; 23(11):1149-50. PubMed ID: 14625174
    [Abstract] [Full Text] [Related]

  • 13. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E.
    Med Klin (Munich); 2002 Jan 15; 97 Suppl 1():2-6. PubMed ID: 11831067
    [Abstract] [Full Text] [Related]

  • 14. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P.
    J Assoc Physicians India; 2005 Apr 15; 53():291-5. PubMed ID: 15987013
    [Abstract] [Full Text] [Related]

  • 15. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res; 2006 Dec 15; 12(24):7374-9. PubMed ID: 17189410
    [Abstract] [Full Text] [Related]

  • 16. [Bone marrow morphologic features in patients treated with imatinib for Philadelphia chromosome positive chronic myeloid leukemia].
    Jiang Q, Chen SS, Jiang B, Jiang H, Shi HL, Lu Y, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Mar 15; 25(3):158-62. PubMed ID: 15182585
    [Abstract] [Full Text] [Related]

  • 17. [Cytogenetic and molecular analysis of 1193 cases with chronic myeloid leukemia].
    Jiang DZ, Chen ZM, Lou JY, Wang YG, Liang Y, Jin J.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan 15; 28(1):1-5. PubMed ID: 17649716
    [Abstract] [Full Text] [Related]

  • 18. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL, Megat Baharuddin PJ, Chin LP, Zakaria Z, Yegappan S, Sathar J, Tan SM, Purushothaman V, Chang KM.
    Cancer Genet Cytogenet; 2008 Jan 01; 180(1):60-4. PubMed ID: 18068536
    [Abstract] [Full Text] [Related]

  • 19. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH.
    Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309
    [Abstract] [Full Text] [Related]

  • 20. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.